Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Receivables (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Change in Receivables data on record, last reported at $827000.0 in Q4 2025.

  • For Q4 2025, Change in Receivables rose 254.94% year-over-year to $827000.0; the TTM value through Dec 2025 reached $316000.0, up 398.11%, while the annual FY2025 figure was $316000.0, 398.11% up from the prior year.
  • Change in Receivables reached $827000.0 in Q4 2025 per LCTX's latest filing, up from -$130000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $827000.0 in Q4 2025 and bottomed at -$50.3 million in Q1 2022.
  • Average Change in Receivables over 5 years is -$2.9 million, with a median of $43000.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: crashed 37374.81% in 2022, then surged 2916.67% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $135000.0 in 2021, then plummeted by 180.0% to -$108000.0 in 2022, then surged by 382.41% to $305000.0 in 2023, then dropped by 23.61% to $233000.0 in 2024, then skyrocketed by 254.94% to $827000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $827000.0 in Q4 2025, -$130000.0 in Q3 2025, and $43000.0 in Q2 2025.